TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Subjects With Radiographic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: WSL-size change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Time Curve (AUC) for Enfuvirtide and Its Metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Wechsler Memory Scale (WMS IV)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: CD4 changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Cold Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Participants That Scheduled an Appointment for PrEP Consultation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent of Participants That Attended an Appointment for PrEP Consultation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent of Participants That Initiated PrEP Use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Degree of enhancement in vasculature images
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proportion of patients requiring paracentesis
Endpoint domain: Adverse events/effects
Primary endpoint: Amount of ascitic fluid extracted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Radiofrequency ablation
Endpoint domain: Surgical and medical procedures outcomes
Primary endpoint: 3 dimensional anthropometric analysis of the cranium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with an antibiotic order within 3 hours of the alert
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: MMR rate at 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of continuous MMR after discontinuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood concentrations of methotrexate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Average Off Time (Hours Per Day) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Systolic Blood Pressure (SBP) ≥180 mmHg and 20 mmHg Increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Diastolic Blood Pressure (DBP) ≥105 mmHg and 15 mmHg Increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Total Epworth Sleepiness Scale (ESS) at Week 12
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Ability to obtain an erection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: ADHD-RS-IV Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Treatment-Emergent Adverse Events (hematology and clinical pathology)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Treatment-Emergent Adverse Events (vital signs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Treatment-Emergent Adverse Events (ECG)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Treatment-Emergent Adverse Events (dermal assessment)
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of imaging the esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Concentrations of DHPG and NE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Army Combat Fitness Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: driving ability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Eradication rate of neoplastic Barrett's Esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 24-hour clearance fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: London tower test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of dengue patients who recover and are discharged
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with Disease severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective pain perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak anti-Xa activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: indices of nutrition, inflammation, and dialysis adequacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Plasma N-terminal Proatrial Natriuretic Peptide (NT proANP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Plasma N-terminal Pro B-type Natriuretic Peptide (NT-proBNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Plasma N-terminal Brain Natriuretic Peptide (BNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Plasma Cyclic Guanine Monophosphate (cGMP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Athletic Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedure-related relevant bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: number of patients with a response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurological Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Detection of polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Children's Depression Inventory score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Sharpe van der Heijde score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Transmitted Light Intensity to Gastric Wall Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Arterial distensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arterial Beta Stiffness Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in cardiac index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Child's Overweight Percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Mass Index z-score (BMI-z)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in gut flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Neurocognitive screening score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Change From Baseline in Diurnal Intraocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time required to complete cystoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time required to visualize ureteral jets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline in the ICIQ-SF score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in the weight of the protective pads
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with an excellent outcome defined by the functional assessments
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Comparison between the HLCM051 and the placebo groups in key adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in HbA1c Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: compliance rate of FOBT completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Achievement of > 75% reduction in PASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of post operative nausea and vomiting (PONV)
Endpoint domain: Adverse events/effects
Primary endpoint: Newcastle Paediatric Mitochondrial Disease Scale (NPMDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restoration of respiratory functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Restoration of the ability to swallow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: decrease in severity of atopic dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of hydroxychloroquine
Endpoint domain: Adverse events/effects
Primary endpoint: Change in white matter health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate cancer free status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in fruit and vegetable preferences
Endpoint domain: Life impact
Endpoint subdomain: Dietary habits
Primary endpoint: Number of people with high serum prolactin result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of patients receiving dopamine agonist treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of patients receiving pituitary MRI scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shrinkage in gastric tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from baseline in CAPS-5 total symptom severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in fear-potentiated startle (FPS) responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in the percent of heavy drinking days (%HDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objectively confirmed thromboembolic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response to the drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days alive free of Transplant and out-of-hospital (DAOH)
Endpoint domain: Mortality/survival
Primary endpoint: Metacognitive precision
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Diagnostic performance for active sacroiliitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Top Embryos Per OPU
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of children with positive PCR or RAD test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of Change in Area of Geographic Atrophy in the Study Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Rate of Change in Area of Geographic Atrophy in the Fellow Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Omega-3 fatty acid levels in serum and fat biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Omega-6 fatty acid levels in serum and fat biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tolerability of omega-3 fatty acid supplementation
Endpoint domain: Adverse events/effects
Primary endpoint: IBS symptom severity (IBS-SSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression of severity Scale (CGI-S)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Solicited Injection Site Reactogenicity Events
Endpoint domain: Adverse events/effects
Primary endpoint: Solicited Systemic Reactogenicity Events
Endpoint domain: Adverse events/effects
Primary endpoint: Serious Adverse Events (SAEs) Considered Study Vaccine-Related
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor metabolic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability of MRI to produce heart images
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Baseline frequency of new users with a diagnosis of COPD including emphysema or chronic bronchitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Overall comorbidity index of new users
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline frequency of patients who have experienced a recent exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Increase in blood oxygen level dependent signal response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of preventable readmissions
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Rivermead Postconcussion Symptoms Questionnaire (RPQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Endothelial cell count concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central cornea thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior chamber reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Healing of Mucosal Ulcerations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: freedom from adverse experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in Total PYY
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Stool Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Return of Spontaneous Circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxaliplatin-Specific Neurotoxicity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Subjects Who Seroconverted for HPV Type 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Who Seroconverted for HPV Type 11
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Who Seroconverted for HPV Type 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Who Seroconverted for HPV Type 18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Who Achieved a Four-fold Rise in Titers to Meningococcal Serogroup A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Overall cost of patient care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in Fractional Exhaled Nitric Oxide (FeNO) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in serum C-reactive protein (CRP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety Lab Evaluations
Endpoint domain: Adverse events/effects
Primary endpoint: Composite Endpoint of DVT, non-fatal PE and Death
Endpoint domain: Mortality/survival
Primary endpoint: Safety Parameter
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of partner abuse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in LogMAR Corrected Distance Visual Acuity (CDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of Bone Formation Marker to Bone Resorption Marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hemorrhage presence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Response rate to NYESO T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Kidney graft survival at month 12
Endpoint domain: Mortality/survival
Primary endpoint: Pancreas graft survival at month 12
Endpoint domain: Mortality/survival
Primary endpoint: Time to significant progression after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative survival period
Endpoint domain: Mortality/survival
Primary endpoint: Percent Change in LDL-C Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of GDM diagnosed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Detection of M. tuberculosis complex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Blood copeptin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Geometric mean titer of SARS-CoV-2 serum neutralizing antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quality of Life (QOS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Treatment Delivery Compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalization for a hyperglycemic emergency
Endpoint domain: Adverse events/effects
Primary endpoint: Change in dCTP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total dose of opioids received in the first 24 hours following Cesarean
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Post-operative pain score at 24 hours post-operatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Aesthetic scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: First morphine dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cumulative morphine dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: correct insertion of vaginal films
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ease of insertion of vaginal film
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement rate of gastric mucosal erosion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Diabetic Retinopathy Worsening or Diabetic Macular Edema Development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Fat thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Less Than Two Lymph Nodes Detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mucositis risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD19+B cell division
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: brain activation and structure as assessed by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Under the Serum Concentration Versus Time Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in GCF tissue plasminogen activator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: change in GCF plasminogen activator inhibitor 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Patient Discomfort With Digoxin Injection (Pain Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for Intubation for Invasive Mechanical Ventilation
Endpoint domain: Adverse events/effects
Primary endpoint: Time to passage of first stool post Caesarean Section
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rates of serum HBVDNA undetectable
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central flap thickness predictability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cardiac Functional Grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Successful Implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: development of symptomatic urinary tract infection
Endpoint domain: Adverse events/effects
Primary endpoint: Radiological Objective Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of local and/or systemic adverse events (AEs)
Endpoint domain: Adverse events/effects